Bibliography for MD7005/MD7255 - Advanced Injectable Therapies BETA

Ajikumar B Aryangat, & John E Gerich. (2010). Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. Vascular Health and Risk Management, 6. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/

Anderson, B., Funnell, M., & American Diabetes Association. (2005). The art of empowerment: stories and strategies for diabetes educators (2nd ed). American Diabetes Association.

Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006). Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabetic Medicine, 23(3), 285–292. https://doi.org/10.1111/j.1464-5491.2005.01781.x

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., Willi, S. M., & Wood, M. A. (2010). Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. New England Journal of Medicine, 363(4), 311–320. https://doi.org/10.1056/NEJMoa1002853

Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016). Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. The Lancet, 388(10057), 2254–2263. https://doi.org/10.1016/S0140-6736(16)31535-5

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008). Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. The Lancet, 371(9618), 1073–1084. https://doi.org/10.1016/S0140-6736(08)60485-7

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes. Annals of Internal Medicine, 154(2). https://doi.org/10.7326/0003-4819-154-2-201101180-00300

Carver, C. (2006). Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. The Diabetes Educator, 32(6), 910–917. https://doi.org/10.1177/0145721706294259

Crasto, W., Jarvis, J., Hackett, E., Nayyar, V., McNally, P. G., Davies, M. J., & Lawrence, I. G. (2009). Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. Postgraduate Medical Journal, 85(1002), 219–222. https://doi.org/10.1136/pgmj.2008.073379

Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., & Jarvis, J. (2015). Development of a self-management education module for those with type 2 diabetes on injectable therapies. Practical Diabetes, 32(8), 305–310a. https://doi.org/10.1002/pdi.1979

Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009a). Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism, 11(12), 1153–1162. https://doi.org/10.1111/j.1463-1326.2009.01154.x

Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009b). Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes, Obesity and Metabolism, 11(12), 1153–1162. https://doi.org/10.1111/j.1463-1326.2009.01154.x

Davies, M. J., Leiter, L. A., Guerci, B., Grunberger, G., Ampudia-Blasco, F. J., Yu, C., Stager, W., Niemoeller, E., Souhami, E., & Rosenstock, J. (2017). Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12980

Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., & Gomis, R. (2005). Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care, 28(6), 1282–1288. https://doi.org/10.2337/diacare.28.6.1282

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. The Lancet, 375(9733), 2234–2243. https://doi.org/10.1016/S0140-6736(10)60406-0

Evans, M., Schumm-Draeger, P. M., Vora, J., & King, A. B. (2011). A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes, Obesity and Metabolism, 13(8), 677–684. https://doi.org/10.1111/j.1463-1326.2011.01395.x

Frandsen, C. S. S., & Madsbad, S. (2014). Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. Diabetic Medicine, 31(11), 1293–1300. https://doi.org/10.1111/dme.12561

Funnell, M. M. (2007). Overcoming Barriers to the Initiation of Insulin Therapy. Clinical Diabetes, 25(1), 36–38. https://doi.org/10.2337/diaclin.25.1.36

Garber, A. J., Ligthelm, R., Christiansen, J. S., & Liebl, A. (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes, Obesity and Metabolism, 9(5), 630–639. https://doi.org/10.1111/j.1463-1326.2006.00654.x

Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study). Diabetes, Obesity and Metabolism, 8(1), 58–66. https://doi.org/10.1111/j.1463-1326.2005.00563.x

Gough, S. C. L. (2007). A review of human and analogue insulin trials. Diabetes Research and Clinical Practice, 77(1), 1–15. https://doi.org/10.1016/j.diabres.2006.10.015

Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013). Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. Diabetes Care, 36(9), 2536–2542. https://doi.org/10.2337/dc12-2329

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016a). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 92(1085), 152–164. https://doi.org/10.1136/postgradmedj-2015-133716

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016b). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. Postgraduate Medical Journal, 92(1085), 152–164. https://doi.org/10.1136/postgradmedj-2015-133716

Heller, S. R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B. H. R., Koelendorf, K., Friberg, H. H., Windfeld, K., & Lindholm, A. (2004). Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabetic Medicine, 21(7), 769–775. https://doi.org/10.1111/j.1464-5491.2004.01244.x

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. Diabetes Care, 29(6), 1269–1274. https://doi.org/10.2337/dc05-1365

Hirsch, I. B., Buse, J. B., Leahy, J., McGill, J. B., Peters, A., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2014a). Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism, 16(3), 206–214. https://doi.org/10.1111/dom.12136

Hirsch, I. B., Buse, J. B., Leahy, J., McGill, J. B., Peters, A., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2014b). Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. Diabetes, Obesity and Metabolism, 16(3), 206–214. https://doi.org/10.1111/dom.12136

Hirsch, I. B., Franek, E., Mersebach, H., Bardtrum, L., & Hermansen, K. (2017). Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST                              T1). Diabetic Medicine, 34(2), 167–173. https://doi.org/10.1111/dme.13068

Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007). Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes. New England Journal of Medicine, 357(17), 1716–1730. https://doi.org/10.1056/NEJMoa075392

Holman, R. R., & Turner, R. C. (1985). A Practical Guide to Basal and Prandial Insulin Therapy. Diabetic Medicine, 2(1), 45–53. https://doi.org/10.1111/j.1464-5491.1985.tb00592.x

Home, P. D. (2012). The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes, Obesity and Metabolism, 14(9), 780–788. https://doi.org/10.1111/j.1463-1326.2012.01580.x

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996a). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD005613.pub3

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996b). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD005613.pub3

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12849

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 38(1), 140–149. https://doi.org/10.2337/dc14-2441

Ismail-Beigi, F. (2012). Glycemic Management of Type 2 Diabetes Mellitus. New England Journal of Medicine, 366(14), 1319–1327. https://doi.org/10.1056/NEJMcp1013127

June  James. (n.d.). Safety and insulin: implementation of national guidance at a local level. Journal of Diabetes Nursing. http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isSerivcesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June&dscnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true

Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015). Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. Diabetes Care, 38(2), 316–322. https://doi.org/10.2337/dc14-0920

L. Luzi. (1989). Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. American Journal of Physiology - Endocrinology and Metabolism, 257(2), E241–E246. http://ajpendo.physiology.org/content/257/2/E241

Leelarathna, L., Roberts, S. A., Hindle, A., Markakis, K., Alam, T., Chapman, A., Morris, J., Urwin, A., Jinadev, P., & Rutter, M. K. (2017). Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. Diabetic Medicine, 34(10), 1372–1379. https://doi.org/10.1111/dme.13412

Luc JC van Loon. (2000). Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. The American Journal of Clinical Nutrition, 72(1), 96–105. http://ajcn.nutrition.org/content/72/1/96.full

MacKinnon, M. (2002). Providing diabetes care in general practice: a practical guide to integrated care (4th ed). Class. https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376

Mäkimattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999). Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia, 42(4), 406–412. https://doi.org/10.1007/s001250051172

Malmberg, K. (1997). Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ, 314(7093), 1512–1512. https://doi.org/10.1136/bmj.314.7093.1512

Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., & Colagiuri, S. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic Medicine, 26(3), 268–278. https://doi.org/10.1111/j.1464-5491.2009.02666.x

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., & Buse, J. B. (2017). Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa1615692

Menting, J. G., Whittaker, J., Margetts, M. B., Whittaker, L. J., Kong, G. K.-W., Smith, B. J., Watson, C. J., Žáková, L., Kletvíková, E., Jiráček, J., Chan, S. J., Steiner, D. F., Dodson, G. G., Brzozowski, A. M., Weiss, M. A., Ward, C. W., & Lawrence, M. C. (2013). How insulin engages its primary binding site on the insulin receptor. Nature, 493(7431), 241–245. https://doi.org/10.1038/nature11781

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 29(8), 1963–1972. https://doi.org/10.2337/dc06-9912

Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diabetes, Obesity and Metabolism, 18(3), 203–216. https://doi.org/10.1111/dom.12591

New IDegLira data show rapid and predictable glycaemic improvements in people with type 2 diabetes. (n.d.). http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/

Pickup, J. C., Reznik, Y., & Sutton, A. J. (2017). Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. Diabetes Care, 40(5), 715–722. https://doi.org/10.2337/dc16-2201

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. (4 C.E.). https://www.youtube.com/watch?v=AhhWTmEFuag

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017a). Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine. https://doi.org/10.1111/dme.13390

Raccah, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017b). Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. Diabetic Medicine, 34(9), 1193–1204. https://doi.org/10.1111/dme.13390

Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., & Garber, A. (2005). Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care, 28(2), 260–265. https://doi.org/10.2337/diacare.28.2.260

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI. (n.d.). http://www.ncbi.nlm.nih.gov/pubmed/18715200

Richard I. G. Holt, ,  Clive Cockram, ,  Allan Flyvbjerg, , and  Barry J. Goldstein. (2016). Textbook of Diabetes. John Wiley & Sons, Incorporated. https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#

Richter, B., & Neises, G. (1996). ‘Human’ insulin versus animal insulin in people with diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD003816.pub2

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. Diabetes Care, 36(9), 2489–2496. https://doi.org/10.2337/dc12-2454

Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., & Thurman, J. (2017). Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. Diabetic Medicine, 34(2), 189–196. https://doi.org/10.1111/dme.13256

Rorsman, P., & Renstr�m, E. (2003). Insulin granule dynamics in pancreatic beta cells. Diabetologia, 46(8), 1029–1045. https://doi.org/10.1007/s00125-003-1153-1

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia, 51(3), 408–416. https://doi.org/10.1007/s00125-007-0911-x

Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014). Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. Diabetes Care, 37(7), 1815–1823. https://doi.org/10.2337/dc13-3055

Rosenstock, J., Raccah, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013). Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care, 36(10), 2945–2951. https://doi.org/10.2337/dc12-2709

Sharon Allard,Caroline Butler,Sue Cradock,Heather Daly,Jemma Edwards,Elizabeth Gilbert. (2010). Using Conversation Maps in practice: the UK experience. Journal of Diabetes Nursing, 14(1). http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962

Srinivasan, B. T., & Davies, M. (2014). Glycaemic management of type 2 diabetes. Medicine, 42(12), 711–717. https://doi.org/10.1016/j.mpmed.2014.09.011

Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008). Recent advances in the management of type 2 diabetes mellitus: a review. Postgraduate Medical Journal, 84(996), 524–531. https://doi.org/10.1136/pgmj.2008.067918

Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (1996). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd. https://doi.org/10.1002/14651858.CD006383.pub2

Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. Diabetic Medicine, 34(9), 1205–1211. https://doi.org/10.1111/dme.13379

Wahren, J., & Kallas, A. (2012). Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? Diabetes, 61(9), 2228–2229. https://doi.org/10.2337/db12-0664

Walker, R. A., Rodgers, J., & Diabetes UK. (2010). Diabetes: a practical guide to managing your health (Fully revised and updated). Dorling Kindersley.

Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017). Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. Diabetes Therapy. https://doi.org/10.1007/s13300-017-0282-3

Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., Hänninen, J., Levänen, H., Lahdenperä, S., Lehtonen, R., & Ryysy, L. (2006). Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia, 49(3), 442–451. https://doi.org/10.1007/s00125-005-0132-0

Young, L. A., & Buse, J. B. (2014). GLP-1 receptor agonists and basal insulin in type 2 diabetes. The Lancet, 384(9961), 2180–2181. https://doi.org/10.1016/S0140-6736(14)61409-4

Zinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., & Mathieu, C. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. The Lancet, 377(9769), 924–931. https://doi.org/10.1016/S0140-6736(10)62305-7